Harbinger Ventures

Harbinger Health is a biotechnology company pioneering a new era of early cancer detection through its proprietary H3 Platform. Launched by Flagship Pioneering in 2021 and led by former FDA Commissioner Dr. Stephen Hahn, the company focuses on identifying cancer at its earliest, most treatable stages. The H3 Platform integrates high-resolution epigenetics with advanced machine learning to detect biological signals of cancer's origins in blood samples. Harbinger Health is currently conducting large-scale clinical validation studies, such as the CORE-MH trial, to support the development of its multi-cancer early detection (MCED) test. The company's mission is to provide an affordable, accessible, and highly accurate diagnostic tool that can be integrated into routine primary care settings globally.